Paratek's Phase III trial of omadacycline shows positive outcome in CABP treatment

US-based biopharmaceutical firm Paratek Pharmaceuticals has reported positive top-line results from its Phase III clinical trial of omadacycline to treat community-acquired bacterial pneumonia (CABP) patients.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news